Multifocal2019Retinitis pigmentosaPerimetryConeGene therapiesDysfunctionMacularSubretinalOphthalmologyRetinal diseasesBaselineIntravitrealVitreousContrastPatientsAdvancementsResponsesDiagnosticOptogeneticsVoretigeneEffectiveClinicalRestorePeripheralDiagnosisDystrophiesCellSignificantlyVision lossDiseaseResponseTrialsOpticalConditionsStudyTreatmentVisual
Multifocal2
- Multifocal ERG Guiding Therapy in a Case of Hydroxychloroquine Premaculopathy. (repositoriosalud.es)
- Multifocal electroretinography (mfERG) showed low density values for ring 1 in both eyes. (repositoriosalud.es)
20192
- Gene therapy was approved for the first time in the UK in 2019 for one of the most severe IRD subtypes, that caused by RPE65 mutations. (ophthalmologybreakingnews.com)
- As a result, approval for the use of Voretigene nepavovec (Luxterna®) was granted in September 2019 as the first gene therapy treatment for IRD. (ophthalmologybreakingnews.com)
Retinitis pigmentosa1
- The clinical variability will make it harder to evaluate the effect of (upcoming) therapies for retinitis pigmentosa, although because of the intraindividual similarity between both eyes, the contralateral eye can be used as an excellent internal control. (eyehospital.nl)
Perimetry1
- Study procedures are anticipated to include manifold quantitative contrast sensitivity testing, RETeval electroretinography, objective field analyzer perimetry, ultrawide field fundus photography and fluorescein angiography, optical coherence tomography and OCT angiography. (marytylermoore.org)
Cone3
- Electroretinography (ERG) shows severely decreased cone function but normal rod function, Pennesi explained. (cgtlive.com)
- Electroretinography may show some residual cone activity, whilst rod activity is usually extinguished. (ophthalmologybreakingnews.com)
- Baseline electroretinography (ERG) showed a high incidence of peripheral cone dysfunction and macular dysfunction on pattern ERG (pERG). (uk.com)
Gene therapies5
- Unfortunately, there are no effective treatments for pigmentary retinopathy, although experimental gene therapies are being tested worldwide. (medicalxpress.com)
- In a presentation at the Association for Research in Vision and Ophthalmology's 2021 virtual annual meeting, Mark Pennesi, MD, PhD, reported preliminary results of 2 ongoing phase 1/2 clinical trials evaluating the effects of subretinal gene therapies for achromatopsia (ACHM). (cgtlive.com)
- Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies. (cgtlive.com)
- Gene therapies are typically delivered to target retinal cells by subretinal (SR) or intravitreal (IVT) injection. (ophthalmologybreakingnews.com)
- Gene therapies are being investigated for multiple inherited retinal diseases and the progress in this field has implications for patient care. (ophthalmologytimes.com)
Dysfunction1
- 31 The electroretinography findings in CAR are illustrative of global retinal dysfunction, with severely reduced, if not extinguished, scotopic and photopic a- and b-waves. (reviewofophthalmology.com)
Macular8
- Full-field Electroretinography in Age-related Macular Degeneration: can retinal electrophysiology predict the subjective visual outcome of cataract surgery? (lu.se)
- To access the effect of vision protection therapy on neovascular conversion in age-related macular degeneration (AMD). (bvsalud.org)
- Purpose: To access the impact of regular periodic subthreshold diode micropulse laser (SDM) as Vision Protection Therapy on the rate of neovascular conversion of dry age-related macular degeneration (AMD). (bvsalud.org)
- Patients with center-involving diabetic macular edema were treated with subthreshold laser therapy. (bvsalud.org)
- For multifactorial diseases such as age-related macular degeneration, for which there is no single underlying genetic cause, gene therapy can provide an additional means of introducing a therapeutic, such as an anti-vascular endothelial growth factor agent. (ophthalmologytimes.com)
- The second study will recruit patients who are beginning intravitreal anti-VEGF therapy for center-involved diabetic macular edema and characterize baseline retinal abnormalities and longitudinal changes over a year of treatment. (marytylermoore.org)
- The primary objective for these studies is to define the ocular structural and functional characteristics of people with diabetes, covering a broad range of diabetes duration and disease severity in eyes over the natural history of the disease and in eyes with center-involved diabetic macular edema undergoing intravitreal anti-vascular endothelial growth factor therapy. (marytylermoore.org)
- And we believe that the exploration of this indirect neuroprotective strategy should lead to the development of novel, accessible and effective molecular therapies for macular degeneration and other neurodegenerative disorders. (brightfocus.org)
Subretinal1
- Gene therapy for RPE-65 IRD is delivered by subretinal injections of modified adeno-associated virus (AAV) with cDNA of RPE65. (ophthalmologybreakingnews.com)
Ophthalmology1
- Developments in technology and therapy possibilities have significantly strengthened the area of vet ophthalmology. (carlsonwagonlit.ca)
Retinal diseases2
- Dr Kay provided an overview of gene therapy and discussed current gene therapy clinical trials and patient counselling pearls for selected inherited retinal diseases. (ophthalmologytimes.com)
- This paper reviews recent advances and potential sources of stem cells for cell therapy in retinal diseases. (biomedcentral.com)
Baseline1
- Vision assessment is recommended at baseline (no later than 4 weeks after starting VIGADRONE), at least every 3 months during therapy, and about 3 to 6 months after the discontinuation of therapy. (rxlist.com)
Intravitreal3
- These include a lentivirus gene therapy trial, a stem cell therapy trial, studies investigating orally administered drugs-one evaluating a chemically modified vitamin A and another examining a visual cycle modulator-and a study of an intravitreal complement inhibitor. (ophthalmologytimes.com)
- The authors suggested that BRC patients require systemic corticosteroids or conventional immunomodulatory therapy to fully control the disease and local intravitreal steroid therapy is insufficient to produce control of choroid inflammation. (uk.com)
- Improved transduction efficiency may allow intravitreal injection to become the preferred route for delivering gene therapy to both the inner and outer retina. (molvis.org)
Vitreous1
- Substantial reduction and even stabilization of both vitreous inflammation and retinal vasculitis have been evident via electroretinography, during daclizumab (IL-2 receptor blocker) therapy. (wikipedia.org)
Contrast1
- In contrast, for dominant diseases in which the mutation is causing protein misfolding or toxicity, gene therapy aims to suppress or inactivate the toxic gene. (ophthalmologytimes.com)
Patients9
- A corticosteroid implant surgically placed within the eye can be used for patients who are not able to achieve remission on or tolerate immunodulatory therapy, or in cases where this option presents less of a burden on life than long-term medical therapy. (wikipedia.org)
- Tolerance to the antihypertensive effect may develop in some patients, necessitating a reevaluation of therapy. (nih.gov)
- Vigadrone (vigabatrin powder) is an anti-epileptic medicine ( anticonvulsant ) indicated as adjunctive therapy for adults and pediatric patients 10 years of age and older with refractory complex partial seizures who have inadequately responded to several alternative treatments and for whom the potential benefits outweigh the risk of vision loss. (rxlist.com)
- This new treatment offers hope for patients and families with IRD but also presents new challenges for the clinician in terms of patient selection, managing expectations, surgical techniques and understanding of the effect of the gene therapy treatment. (ophthalmologybreakingnews.com)
- The clinical trials data for Voretigene gene therapy for RPE65 IRD have been evaluated by the National Institute for Health and Care Excellence (NICE) and the improvement in mobility and functional vision, even though it was a small change, was considered important for affected patients. (ophthalmologybreakingnews.com)
- In the UK, there are three centres approved for gene therapy treatment for patients with RPE65 IRD (Oxford, London and Manchester), and this article describes the process set up in Manchester (by the Manchester Ocular Gene Therapy Group) for the optimum delivery and assessment of this new treatment. (ophthalmologybreakingnews.com)
- As reported by Medscape Medidcal News , in a small study, he and his colleagues showed that patients with ADHD displayed significantly elevated "background noise" on pattern electroretinography compared with their healthy peers. (medscape.com)
- Dr. Francis also uses PERG in patients diagnosed with glaucoma to monitor their response to medical, surgical, or laser therapy. (aao.org)
- Regarding the clinical findings, disease was highly symmetrical between the right and left eyes and visual impairment was mild or moderate in 90% of patients, providing a window of opportunity for gene therapy. (ox.ac.uk)
Advancements1
- With advancements in technology and therapy options, vet ophthalmologists can provide adequate care for pet eye issues, from routine check-ups to complicated surgeries. (carlsonwagonlit.ca)
Responses1
- However, one potential barrier to efficacious long-term therapy is the development of immune responses against the vector or transgene product. (ox.ac.uk)
Diagnostic2
- With advanced diagnostic devices such as ocular ultrasound and electroretinography, vets can effectively diagnose eye conditions in animals. (carlsonwagonlit.ca)
- The researchers used various diagnostic techniques-electroretinography (ERG), measurement of optomotor response (OMR), evoked visual potentials (VEP), and electrophysiology of single neurons in the primary visual cortex (V1). (medicalxpress.com)
Optogenetics2
- Advancement of new therapeutic interventions such as optogenetics gene therapy and cell replacement therapies are dependent on electrophysiological measurements at cellular resolution. (nature.com)
- Non-genotype specific gene therapy using neuromodulation or optogenetics is an approach employed when the causative gene for a disease is not known. (ophthalmologytimes.com)
Voretigene1
- The first retinal gene therapy, voretigene neparvovec-rzyl (Luxturna, Spark Therapeutics), was approved by the United States Food and Drug Administration in 2017. (ophthalmologytimes.com)
Effective5
- To date, effective therapies have not been developed. (mdpi.com)
- Immunosuppressant therapy along with oral corticosteroid has been somewhat effective in slowing down the progressive inflammation associated with the disorder, preserving visual integrity as much as possible. (wikipedia.org)
- Consistent with two prior studies, the current study finds Vision Protection Therapy markedly more effective at both recognizing and preventing neovascular AMD than the current standard of care, benefiting the highest risk dry AMD eyes the most. (bvsalud.org)
- The data support the notion that rAAV.sFlt-1 gene therapy is safe and effective for the long-term inhibition of deleterious blood vessel growth in the eye. (edu.au)
- While no effective treatment for CAR exists, long-term immunosuppression remains the mainstay of therapy. (reviewofophthalmology.com)
Clinical1
- Two clinical trials of the affected genes are underway, one is a long-term follow-up gene therapy study for achromatopsia CNGB3 and CNGA3, at the Moorfields Eye Hospital, London, and Kellogg Eye Center, Ann Arbor, MI, and the other is a natural history study of achromatopsia CNGB3 and CNGA3, at Moorfields Eye Hospital. (cgtlive.com)
Restore1
- These therapies are designed to slow disease progression and hopefully restore visual function. (ophthalmologybreakingnews.com)
Peripheral1
- During long‑term therapy, cardiac output tends to return to control values, while peripheral resistance remains decreased. (nih.gov)
Diagnosis3
- With quick diagnosis and therapy, numerous eye conditions in pets can be addressed quickly to keep their quality of life. (carlsonwagonlit.ca)
- Electroretinography helps confirm the diagnosis. (msdmanuals.com)
- Diagnosis is by funduscopy, usually supplemented with electroretinography. (msdmanuals.com)
Dystrophies1
- Gene therapy for retinal dystrophies involves several different techniques that vary depending on the type of mutation. (ophthalmologytimes.com)
Cell2
- Stem cell (SC) therapy is not a new concept. (biomedcentral.com)
- To identify proper targets for such a therapy, we combine the advances in automated microscopy with the methods of stem cell biology and genetic engineering. (brightfocus.org)
Significantly1
- Also, new therapy solutions, such as cataract surgery and corneal transplants, can significantly improve the quality of life for pets with severe eye disorders. (carlsonwagonlit.ca)
Vision loss1
- Research conducted by an international team of scientists, with the participation of Dr. Andrzej Foik of ICTER, may help develop therapies to slow vision loss. (medicalxpress.com)
Disease2
- In gene replacement therapy, a disease-causing gene is replaced with a functional copy of the gene. (ophthalmologybreakingnews.com)
- CNGB3-achromatopsia is another disease for which there are ongoing gene therapy trials. (ophthalmologytimes.com)
Response2
- To determine the efficacy of rAAV.sFlt-1-mediated gene therapy in a transgenic mouse model of retinal neovascularization (trVEGF029) and to assess whether rAAV.sFlt-1 administration generated any deleterious, long-lasting immune response that could affect efficacy. (edu.au)
- We have an ability to non-invasively study retinal structure and response to light using optical coherence tomography and electroretinography. (brightfocus.org)
Trials1
- Current gene therapy trials for Leber congenital amaurosis (LCA) include one involving antisense oligonucleotide therapy and another using a CRISPR system for gene editing. (ophthalmologytimes.com)
Optical1
- Although pharmacologic manipulation of intrinsically photosensitive retinal ganglion cells and the neural pathways that mediate photophobia may be possible in the future, current therapies are directed at the underlying cause of the photophobia and optical modulation of these cells and pathways. (researchgate.net)
Conditions1
- It is possible to distinguish between the two conditions by using electroretinography or, more easily, genetic testing. (ophthalmologytimes.com)
Study1
- The study has many strengths, starting with an easy approach to the patient by investigating the visual system and documenting a normalization after therapy," Dr. Bubl commented. (medscape.com)
Treatment2
- Treatment of thallium toxicity consists of initial stabilization, prevention of absorption, enhanced elimination, and antidotal therapy. (medscape.com)
- Vulnerability to the reduction in natural light associated with fall/winter is generally accepted as the main trigger of seasonal affective disorder (SAD), whereas light therapy is a treatment of choice of the disorder. (ulaval.ca)
Visual1
- The relative preservation in childhood of retinal structure and modest visual function opens up the possibility of restoring function by gene therapy in this subtype of IRD. (ophthalmologybreakingnews.com)